BioCentury
ARTICLE | Company News

Knight Therapeutics infectious news

August 18, 2014 7:00 AM UTC

Knight hired an investment bank to sell its neglected tropical disease Priority Review voucher. Knight received the voucher from FDA in March following the approval of leishmaniasis drug Impavido miltefosine under the agency’s Tropical Disease Priority Review voucher program. The transferrable voucher entitles the bearer to obtain Priority Review of any subsequent NDA or BLA that otherwise would receive a standard review, thus reducing the time for review to six months from 10 (see BioCentury, March 24).

Last month, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN, Novato, Calif.) sold a Priority Review voucher to Regeneron Pharmaceuticals Inc. (NASDAQ:REGN, Tarrytown, N.Y.) and partner Sanofi (Euronext:SAN;NYSE:SNY, Paris, France) for $67.5 million (see BioCentury, Aug. 4). ...